This strategy aims to provide a complementary enhancement of the immune system at the level of the tumor microenvironment, by blocking the PD-1/PD-L1 pathway, and at the level of peripheral lymphoid organs, by increasing the recruitment of T lymphocytes with antitumor activity through the CTLA-4 pathway [69,70]. Here, RPL17 is linked to neoplasm.